D W Dowdy1, M A O'Brien, D Bishai. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. david.w.dowdy@gmail.com
Abstract
SETTING: The potential cost-effectiveness of improved diagnostic tests for tuberculosis (TB) in resource-limited settings is unknown. OBJECTIVE: To estimate the incremental cost-effectiveness of a hypothetical new point-of-care TB diagnostic test in South Africa, Brazil and Kenya. DESIGN: Decision-analysis model, adding four diagnostic interventions (sputum smear microscopy, new test, smear plus new test and smear plus TB culture) to a baseline of existing infrastructure without smear. RESULTS: Adding sputum smear was estimated to be more cost-effective (incremental cost per disability-adjusted life year [DALY] of $86 [South Africa], $131 [Brazil], $38 (Kenya]) than a new TB diagnostic with 70% sensitivity, 95% specificity and price of $20 per test ($198 [South Africa], $275 [Brazil], $84 [Kenya]). However, compared to sputum smear, smear plus new test averted 46-49% more DALYs per 1000 TB suspects (321 vs. 215 [South Africa], 243 vs. 166 [Brazil], 790 vs. 531 [Kenya]), at an incremental cost of $170 (Kenya) to $625 (Brazil) per DALY averted. Cost-effectiveness was most sensitive to the specificity and price of the new test, the baseline TB case detection rate and the discount rate. CONCLUSION: Novel diagnostic tests for TB are potentially highly cost-effective. Cost-effectiveness is maximized by high-specificity, low-cost tests deployed to regions with poor infrastructure.
SETTING: The potential cost-effectiveness of improved diagnostic tests for tuberculosis (TB) in resource-limited settings is unknown. OBJECTIVE: To estimate the incremental cost-effectiveness of a hypothetical new point-of-care TB diagnostic test in South Africa, Brazil and Kenya. DESIGN: Decision-analysis model, adding four diagnostic interventions (sputum smear microscopy, new test, smear plus new test and smear plus TB culture) to a baseline of existing infrastructure without smear. RESULTS: Adding sputum smear was estimated to be more cost-effective (incremental cost per disability-adjusted life year [DALY] of $86 [South Africa], $131 [Brazil], $38 (Kenya]) than a new TB diagnostic with 70% sensitivity, 95% specificity and price of $20 per test ($198 [South Africa], $275 [Brazil], $84 [Kenya]). However, compared to sputum smear, smear plus new test averted 46-49% more DALYs per 1000 TB suspects (321 vs. 215 [South Africa], 243 vs. 166 [Brazil], 790 vs. 531 [Kenya]), at an incremental cost of $170 (Kenya) to $625 (Brazil) per DALY averted. Cost-effectiveness was most sensitive to the specificity and price of the new test, the baseline TB case detection rate and the discount rate. CONCLUSION: Novel diagnostic tests for TB are potentially highly cost-effective. Cost-effectiveness is maximized by high-specificity, low-cost tests deployed to regions with poor infrastructure.
Authors: David W Dowdy; Richard E Chaisson; Gary Maartens; Elizabeth L Corbett; Susan E Dorman Journal: Proc Natl Acad Sci U S A Date: 2008-08-11 Impact factor: 11.205
Authors: Paul K Drain; Emily P Hyle; Farzad Noubary; Kenneth A Freedberg; Douglas Wilson; William R Bishai; William Rodriguez; Ingrid V Bassett Journal: Lancet Infect Dis Date: 2013-12-10 Impact factor: 25.071
Authors: Marco Schito; Trevor F Peter; Sean Cavanaugh; Amy S Piatek; Gloria J Young; Heather Alexander; William Coggin; Gonzalo J Domingo; Dennis Ellenberger; Eugen Ermantraut; Ilesh V Jani; Achilles Katamba; Kara M Palamountain; Shaffiq Essajee; David W Dowdy Journal: J Infect Dis Date: 2012-03-29 Impact factor: 5.226
Authors: Mandeep S Jassal; Gueno G Nedeltchev; Jong-Hee Lee; Seong Won Choi; Viorel Atudorei; Zachary D Sharp; Vojo Deretic; Graham S Timmins; William R Bishai Journal: PLoS One Date: 2010-08-27 Impact factor: 3.240
Authors: Maunank Shah; Ebrahim Variava; Charles B Holmes; Alison Coppin; Jonathan E Golub; Jeremy McCallum; Michelle Wong; Binu Luke; Desmond J Martin; Richard E Chaisson; Susan E Dorman; Neil A Martinson Journal: J Acquir Immune Defic Syndr Date: 2009-10-01 Impact factor: 3.731